GlassScriptPhysician profile
Sara Nabil Khalil
NPI 1699157214
$5,956.86
in general payments reported to CMS, 2019-2025
43 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $517 · 2021: $782 · 2022: $1,035 · 2023: $729 · 2024: $668 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $825.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $781.85 | 2019-2025 | |
| Novo Nordisk INC | $738.75 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $506.39 | 2019-2022 | |
| Astellas Pharma US INC | $444.92 | 2019-2025 | Veozah |
| Amgen INC. | $440.01 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Pfizer INC. | $357.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $194.39 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $173.94 | 2020-2022 | |
| Lilly USA, LLC | $155.44 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $153.57 | 2022-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $120.78 | 2019-2021 | |
| Amarin Pharma, INC. | $117.65 | 2020-2022 | |
| Exact Sciences Corporation | $111.92 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $92.76 | 2024-2025 | Rexulti |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.